Zacks All-Star Analyst Issues Recommendations For ELI, HEB, MATK, BTRN
CHICAGO, IL, Sep 17, 2001 (INTERNET WIRE via COMTEX) -- Dr. Vandana Bapna pronounces the 21st century as "the Biotech century." The Offutt Securities Analyst's recommendations are up 52% through June, and she is picking stocks outside of most other analysts' radars! They are: Elite Pharmaceuticals, Inc. (AMEX: ELI chart, msgs), Hemispherx Biopharma, Inc. (AMEX: HEB chart, msgs), Martek Biosciences Corporation (NASDAQ: MATK chart, msgs), and BioTransplant Incorporated (NASDAQ: BTRN chart, msgs). For the complete report and substantially more extensive commentary on the sector, visit www.Picks2.Zacks.com
Here are the details on Analyst Dr. Vandana Bapna's Stock Picks for today:
Elite Pharmaceuticals, Inc. (AMEX: ELI chart, msgs)
Elite engages in developing, manufacturing and commercializing oral drug delivery technology-based products for the existing drugs. The drugs are formulated in such a way that they are delivered into the bloodstream at pre-determined rates and pre-determined times to increase effectiveness, reduce side effects, increase convenience, and help address compliance issues.
Hemispherx Biopharma, Inc. (AMEX: HEB chart, msgs)
Hemispherx Biopharma focuses on patented ribo-nucleic acid (RNA) products that stimulate the body's natural anti-viral defense system. The drug, Ampligen, is most heavily tested and closest to approval for Chronic Fatigue Syndrome. This represents a very large and untapped market including 500,000 patients in each of the United States, rest of the world and expects for prescriptions to generate revenues of $15,000 per patient with 50% margins.
Martek Biosciences Corporation (NASDAQ: MATK chart, msgs)
Martek develops, manufactures, and markets oils (DHA and ARA) derived from micro-algae that are shown to regulate liver functions and facilitate retinal, cardiac and nerve activity. These naturally occurring oils are found optimally in breast milk, but Martek has developed them as additives to infant formula, as well as is developing them as prenatal supplements and for adults. The product is found to, on average, stimulate a 7-point IQ boost in 18-month old babies that widens as they mature. BioTransplant Incorporated (NASDAQ: BTRN chart, msgs)
BioTransplant is Dr. Bapna's long-term investment choice. The company has a rich product pipeline currently in clinical trials. Its products are focused on facilitating organ transplants by boosting the body's natural ability to accept foreign cells as its own redressing toxicity and dependence issues for existing treatments. The product, called Medi-507 and complementary products are cross-licensed with MedImmune as stand-alone product and used for Allomune system (for organ transplants and cancers) and for XenoMune system (for cross-species transplants). The company has an excellent patent portfolio, contends Bapna and feels the company is currently under-valued.
Be sure to read the rest of the article to learn all the stocks this top analyst is recommending now. www.AllStarPicks1.Zacks.com
About Zacks All Star Analyst Survey
Do you want to know which brokerage analysts are the best stock pickers in their field and what stock they're recommending today? Find out with the Zacks All Star Analyst survey.
This exclusive survey, created with Fortune Magazine, reveals the "Best-of-Breed" brokerage analysts. They are the select group of winners from a field of 5,500 brokerage analysts - the ones who consistently beat the street - the few you should be following. Visit www.Profit2.Zacks.com
Stock Picks from All Star Analysts Highlighted in FREE Investment Newsletter Each week, Zacks Investment Research highlights another All Star Analyst and their hottest stock picks in the FREE e-mail newsletter, "Profit from the Pros." You'll also discover the "All Star Portfolio," the exclusive stock list comprised only of stocks where 4 or more All Star Analysts consider it a strong buy. The only way to get these powerful insights is with a FREE subscription to the "Profit from the Pros" investment newsletter. Just visit www.Profit3.Zacks.com
About Zacks |
